Previous 10 | Next 10 |
Curis to Host Virtual Event to Discuss CA-4948 Clinical Data LEXINGTON, Mass. , Dec. 2, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that i...
Curis ([[CRIS]] +1.8%) has entered into a Cooperative Research and Development Agreement with the National Cancer Institute ((NCI)), part of National Institutes of Health, for joint development of CA-4948 as an anti-cancer agent.Under the agreement, Curis will collaborate with the NCI to cond...
Curis, Inc. (CRIS) Q3 2020 Earnings Conference Call November 10, 2020 04:30 PM ET Company Participants Bill Steinkrauss - Chief Financial Officer Jim Dentzer - President & Chief Executive Officer Bob Martell - Head of R&D Conference Call Participants Yale Jen - Laidlaw & Company S...
Curis (CRIS): Q3 GAAP EPS of -$0.11 beats by $0.06.Revenue of $2.74M (-4.2% Y/Y) beats by $0.09M.As of September 30, 2020, Curis' cash, cash equivalents, marketable securities and investments totaled $23.6 million and there were approximately 56.7 million shares of common stock outstanding. C...
Curis Reports Third Quarter 2020 Financial Results - Clinical data in CA-4948 NHL and AML/MDS trials to be presented in oral presentation and poster sessions at ASH - - Patient Dosing initiated in Phase 1a/1b trial of anti-VISTA monoclonal antibody, CI-8993, in advanced refr...
Curis Announces Collaboration with the National Cancer Institute for the Development of IRAK4 Inhibitor, CA-4948, as an Anti-Cancer Agent PR Newswire LEXINGTON, Mass., Nov. 10, 2020 LEXINGTON, Mass. , Nov. 10, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ...
Curis Announces Three Abstracts for CA-4948 Accepted for Presentation at the 62nd American Society of Hematology Annual Meeting and Exposition PR Newswire LEXINGTON, Mass., Nov. 4, 2020 LEXINGTON, Mass. , Nov. 4, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ:...
Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference Curis to Present at H.C. Wainwright & Co. 6th Annual Israel Conference PR Newswire LEXINGTON, Mass., Nov. 4, 2020 LEXINGTON, Mass. , Nov. 4, 2020 /PRNewswire/ -- Curis, In...
Curis to Release Third Quarter 2020 Financial Results and Hold Conference Call on November 10, 2020 PR Newswire LEXINGTON, Mass., Nov. 2, 2020 LEXINGTON, Mass. , Nov. 2, 2020 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the d...
Curis Highlights Publication in ACS Medicinal Chemistry Letters Showcasing Targeted Potency and Ideal Pharmacologic Properties of CA-4948 for Treatment of Hematologic Malignancies PR Newswire LEXINGTON, Mass., Oct. 21, 2020 LEXINGTON, Mass. , Oct. 21, 2020 /P...
News, Short Squeeze, Breakout and More Instantly...
2024-07-15 17:46:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Curis to Present at Upcoming Healthcare Conference in July PR Newswire LEXINGTON, Mass. , July 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IR...
2024-05-25 08:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...